Researchers at Massachusetts General Hospital in Boston published results from a long-term clinical trial of a tuberculosis vaccine in type 1 diabetes patients that in a long-term follow-up appears to have cured the disease.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Novo Nordisk’s experimental diabetes pill, which the company hopes will transform the diabetes market, has proved superior to both Merck & Co.’s Januvia and its own best-selling injectable treatment Victoza in tests.
New York-based Kallyope and Danish company Novo Nordisk signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.
The U.S. FDA approved for marketing DreaMed Diabetes’ Advisor Pro software to help manage diabetes treatment.
Novo Nordisk said data from a large final-stage study of a pill the company hopes will transform the diabetes market proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim’s established Jardiance.
Many restaurants, supermarkets, convenience stores and movie theaters across the United States are required to start clearly displaying food calorie counts as part of a push to trim expanding American waistlines and control healthcare costs.
Shares of Adocia were up nearly 30 percent after the French company granted exclusive development and commercialization rights of its insulin products to Tonghua Dongbao Pharmaceuticals in order to provide treatment to the 100 million people in China living with a form of diabetes.
The U.S. Food and Drug Administration approved Sanofi’s Toujeo (insulin glargine 300 Units/mL) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the market.
AstraZeneca Pharmaceuticals LP’s drug Farxiga could receive a new indication for a subset of diabetes patients based on Phase III data that was released.